[Aplastic anemia and viral hepatitis (posthepatitic aplastic anemia)].
OBJECTIVE
To validate up-to-date policy of immunosuppressive therapy of patients with aplastic anemia (AA) which has developed either at acute or chronic phase of viral hepatitis.


METHODS
16 patients with AA detected within 6 months (9 patients) or 12-36 months (7 patients) after acute viral hepatitis received immunosuppressive therapy (antilymphocytic globulin, cyclosporin A, splenectomy).


RESULTS
Posthepatitis aplastic anemias ran a severe and treatment-resistant course in most cases. The immunosuppressive therapy produced a response in 44% of the patients. AA following acute viral hepatitis demands intensive and long-term immunosuppressive therapy with antilymphocytic globulin, cyclosporin A, splenectomy (in some cases) to achieve a persistent clinicohematological remission.
Mikhaĭlova
E A
EA
Iadrikhinskaia
V N
VN
Savchenko
V G
VG
D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000209:etiology* / Q000628:therapy; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006525:Hepatitis, Viral, Human / Q000150:complications*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D013156:Splenectomy; D013997:Time Factors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016572:Cyclosporine